345 related articles for article (PubMed ID: 32590192)
1. Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery.
Chen B; Gao A; Tu B; Wang Y; Yu X; Wang Y; Xiu Y; Wang B; Wan Y; Huang Y
Biomaterials; 2020 Oct; 255():120187. PubMed ID: 32590192
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53
Qiu J; Feng M; Yang G; Cao Z; Liu Y; You L; Zhang T
Cancer Lett; 2023 Feb; 554():216020. PubMed ID: 36442772
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.
Pu Y; Ji Q
Front Immunol; 2022; 13():874589. PubMed ID: 35592338
[TBL] [Abstract][Full Text] [Related]
5. Reversing tumor immunosuppressive microenvironment via targeting codelivery of CpG ODNs/PD-L1 peptide antagonists to enhance the immune checkpoint blockade-based anti-tumor effect.
Zhang M; Fang Z; Zhang H; Cui M; Wang M; Liu K
Eur J Pharm Sci; 2022 Jan; 168():106044. PubMed ID: 34666183
[TBL] [Abstract][Full Text] [Related]
6. Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery.
Zheng Z; Zhang J; Jiang J; He Y; Zhang W; Mo X; Kang X; Xu Q; Wang B; Huang Y
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817393
[TBL] [Abstract][Full Text] [Related]
7. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Pang L; Han S; Jiao Y; Jiang S; He X; Li P
Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
[TBL] [Abstract][Full Text] [Related]
8. Role of mTOR Signaling in Tumor Microenvironment: An Overview.
Conciatori F; Bazzichetto C; Falcone I; Pilotto S; Bria E; Cognetti F; Milella M; Ciuffreda L
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126252
[TBL] [Abstract][Full Text] [Related]
9. Remodeling "cold" tumor immune microenvironment
He Y; Fang Y; Zhang M; Zhao Y; Tu B; Shi M; Muhitdinov B; Asrorov A; Xu Q; Huang Y
Acta Pharm Sin B; 2022 Apr; 12(4):2057-2073. PubMed ID: 35847495
[TBL] [Abstract][Full Text] [Related]
10. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer.
Yagi T; Baba Y; Okadome K; Kiyozumi Y; Hiyoshi Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
Eur J Cancer; 2019 Apr; 111():38-49. PubMed ID: 30822683
[TBL] [Abstract][Full Text] [Related]
11. Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1.
Wang H; Tang Y; Fang Y; Zhang M; Wang H; He Z; Wang B; Xu Q; Huang Y
Nano Lett; 2019 May; 19(5):2935-2944. PubMed ID: 30950276
[TBL] [Abstract][Full Text] [Related]
12. PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1
Kim EH; Lee J; Kwak G; Jang H; Kim H; Cho H; Jang Y; Choi J; Chi SG; Kim K; Kwon IC; Yang Y; Kim SH
J Control Release; 2022 May; 345():62-74. PubMed ID: 35263615
[TBL] [Abstract][Full Text] [Related]
13. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
14. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
[TBL] [Abstract][Full Text] [Related]
15. A PD-L1-targeting Regulator for Metabolic Reprogramming to Enhance Glutamine Inhibition-Mediated Synergistic Antitumor Metabolic and Immune Therapy.
Jin XK; Zhang SM; Liang JL; Zhang SK; Qin YT; Huang QX; Liu CJ; Zhang XZ
Adv Mater; 2024 Feb; 36(6):e2309094. PubMed ID: 38014890
[TBL] [Abstract][Full Text] [Related]
16. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
17. Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFR
Yin W; Yu X; Kang X; Zhao Y; Zhao P; Jin H; Fu X; Wan Y; Peng C; Huang Y
Small; 2018 Nov; 14(47):e1802372. PubMed ID: 30307695
[TBL] [Abstract][Full Text] [Related]
18. Enhanced response to PD-L1 silencing by modulation of TME via balancing glucose metabolism and robust co-delivery of siRNA/Resveratrol with dual-responsive polyplexes.
Jia L; Gao Y; Zhou T; Zhao XL; Hu HY; Chen DW; Qiao MX
Biomaterials; 2021 Apr; 271():120711. PubMed ID: 33592352
[TBL] [Abstract][Full Text] [Related]
19. Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment.
Bazzichetto C; Conciatori F; Falcone I; Ciuffreda L
Adv Exp Med Biol; 2020; 1223():69-80. PubMed ID: 32030685
[TBL] [Abstract][Full Text] [Related]
20. Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment.
Tu B; He Y; Chen B; Wang Y; Gao Y; Shi M; Liu T; Asrorov AM; Huang Y
Biomater Sci; 2020 Dec; 8(24):7166-7176. PubMed ID: 33169732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
